Enhanced External Counter Pulsation on Afterload Mismatch Rate in Post-TEER (PAMPER)

NCT ID: NCT06227286

Last Updated: 2024-02-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

176 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-01

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this multicenter, randomized, double-blind controlled study is to learn about the individuals after transcatheter edge-to-edge mitral valve repair (TEER). The main questions it aims to answer are: (1) can enhanced external counterpulsation (EECP) reduce the prevalence of afterload mismatch after TEER? (2) can EECP prevent the major adverse cardiac events after TEER? Participants will be randomly assigned into EECP or Sham-EECP intervention after TEER. Researchers will compare the EECP and Sham-EECP to see if it helps reduce the prevalence of afterload mismatch after TEER.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mitral Regurgitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EECP Arm

Participants would be assigned for treating with EECP initiated with 0.030 MPa, 30-45 minutes per day, 5 days per week, 7 weeks in total.

Group Type EXPERIMENTAL

EECP

Intervention Type DEVICE

EECP: 30-45 minutes/day, 5 days/week, 7 weeks, initiates with 0.030MPa.

Sham-EECP Arm

Participants would be assigned for treating with Sham-EECP initiated with 70 mmHg, 30-45 minutes per day, 5 days per week, 7 weeks in total.

Group Type SHAM_COMPARATOR

Sham-EECP

Intervention Type DEVICE

EECP: 30-45 minutes/day, 5 days/week, 7 weeks, constant to 75 mmHg.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EECP

EECP: 30-45 minutes/day, 5 days/week, 7 weeks, initiates with 0.030MPa.

Intervention Type DEVICE

Sham-EECP

EECP: 30-45 minutes/day, 5 days/week, 7 weeks, constant to 75 mmHg.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Consent to participate
* Age \> 18 years
* Moderate or severe Mitral Regurgitation
* Patients who meet the indications for transcatheter Mitral valve edge-to-edge repair and have undergone TEERM

Exclusion Criteria

* Lower extremity deep vein thrombosis, active thrombophlebitis
* Moderate or severe aortic stenosis/insufficiency
* Moderate pulmonary hypertension (mean pulmonary pressure \>50mmHg)
* Aortic aneurysm/cerebral aneurysm Uncontrolled hypertension (\>180/110mmHg) Arrhythmias that may interfere with the ECG gating function of the EECP device Hemorrhagic disease or obvious bleeding tendency Limb infection Pregnant/lactating women
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

First Affiliated Hospital, Sun Yat-Sen University

OTHER

Sponsor Role collaborator

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

Sponsor Role collaborator

Second Affiliated Hospital of Shantou University Medical College

OTHER

Sponsor Role collaborator

Second Affiliated Hospital of Guangzhou Medical University

OTHER

Sponsor Role collaborator

Zhongshan People's Hospital, Guangdong, China

OTHER

Sponsor Role collaborator

Jieyang People's Hospital

OTHER

Sponsor Role collaborator

Sun Yat-sen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xiao-dong Zhuang

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xiaodong Zhuang, PhD

Role: PRINCIPAL_INVESTIGATOR

First Affiliated Hospital, Sun Yat-Sen University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

First Affiliated Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, China

Site Status

Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

Site Status

Third Affiliated Hospital, Sun Yat-Sun University

Guangzhou, Guangdong, China

Site Status

Jieyang People's Hospital

Jieyang, Guangdong, China

Site Status

Second Affiliated Hospital of Shantou University Medical College

Shantou, Guangdong, China

Site Status

Zhongshan People's Hospital

Zhongshan, Guangdong, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Xiaodong Zhuang, PhD

Role: CONTACT

+86 13760755035

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Xiaodong Zhuang, PhD

Role: primary

+86 13760755035

Longgen Xiong

Role: primary

+8613922761639

Zhuoshan Huang, PhD

Role: primary

+86 13728059476

Mingwei Xu, PhD

Role: primary

+86 13828186368

Jilin Li, PhD

Role: primary

+86 13592852807

Li Feng, PhD

Role: primary

+86 13902593410

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PAMPER Study

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.